Public Employees Retirement System of Ohio raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 14.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 361,650 shares of the medical research company’s stock after purchasing an additional 44,877 shares during the quarter. Public Employees Retirement System of Ohio owned 0.17% of Edwards Lifesciences Corporation worth $42,761,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. ETF Managers Group LLC acquired a new stake in Edwards Lifesciences Corporation during the 2nd quarter valued at $112,000. Shine Investment Advisory Services Inc. acquired a new stake in Edwards Lifesciences Corporation during the 2nd quarter valued at $126,000. Cornerstone Advisors Inc. increased its stake in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after acquiring an additional 219 shares during the last quarter. Alexandria Capital LLC increased its stake in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after acquiring an additional 19 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new position in shares of Edwards Lifesciences Corporation in the second quarter worth $149,000. 82.12% of the stock is currently owned by institutional investors.

WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/14/edwards-lifesciences-corporation-ew-holdings-increased-by-public-employees-retirement-system-of-ohio.html.

In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $114.68, for a total transaction of $607,804.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Catherine M. Szyman sold 4,681 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Insiders have sold a total of 182,201 shares of company stock worth $20,768,154 over the last 90 days. 2.13% of the stock is owned by company insiders.

Edwards Lifesciences Corporation (NYSE EW) traded down 1.77% during midday trading on Friday, reaching $108.25. 1,446,300 shares of the company’s stock were exchanged. The company has a market cap of $22.86 billion, a price-to-earnings ratio of 32.83 and a beta of 0.62. The firm has a 50-day moving average price of $111.39 and a 200 day moving average price of $111.32. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.20. The company had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.76 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

A number of equities analysts have recently weighed in on EW shares. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $130.00 price target (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target on the stock in a research note on Tuesday, July 18th. SunTrust Banks, Inc. upped their price target on shares of Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Jefferies Group LLC upped their price target on shares of Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $120.75.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.